GLP-1, or Glucagon-like Peptide-1, is an incretin hormone secreted by L-cells in the distal small intestine primarily in response to nutrient ingestion, playing a pivotal role in glucose homeostasis and satiety signaling. Its actions are crucial for modulating postprandial insulin secretion and suppressing glucagon release. Clinically, it represents a key target for managing metabolic dysregulation.
Origin
The term originates from its chemical structure, identifying it as a peptide derived from proglucagon, found in the gut (Gastrointestinal tract). Its physiological significance became apparent through studies linking nutrient sensing in the gut to pancreatic endocrine function. It is a vital component of the entero-insular axis.
Mechanism
GLP-1 exerts its effects by binding to the GLP-1 receptor (GLP-1R) on pancreatic beta cells, leading to glucose-dependent insulin secretion, which enhances peripheral glucose uptake. Furthermore, it acts centrally to increase satiety signals and peripherally to slow gastric emptying, reducing the rate of substrate entry into circulation. These combined actions contribute significantly to blunting postprandial hyperglycemia.
Strategically combining hormonal protocols and peptide therapies creates a synergistic effect, enhancing overall metabolic health and physiological function.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.